We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.25 | -2.22% | 11.00 | 251,902 | 14:15:38 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.50 | 11.50 | 11.25 | 10.75 | 11.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 2.19M | -1.44M | -0.0232 | -4.74 | 6.98M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:08:28 | O | 350 | 10.62 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/12/2024 | 12:39 | ALNC |  RUA Life Sciences swings to pretax profit in its first half |
| 11/12/2024 | 07:00 | UK RNS | RUA Life Sciences PLC Interim Results |
| 30/10/2024 | 07:00 | UK RNS | RUA Life Sciences PLC Trading Update & Change of Accounting Date |
| 09/9/2024 | 11:31 | ALNC | RUA Life Sciences buys Analytic Biosurgical Solutions for EUR80,000 |
| 09/9/2024 | 06:00 | UK RNS | RUA Life Sciences PLC Acquisition |
| 28/8/2024 | 06:00 | UK RNS | RUA Life Sciences PLC Result of AGM |
| 27/8/2024 | 18:34 | ALNC | TRADING UPDATES: Shield Therapeutics lands Canada win; RUA revenue up |
| 27/8/2024 | 06:00 | UK RNS | RUA Life Sciences PLC AGM Statement and Trading Update |
| 24/7/2024 | 10:53 | ALNC | RUA Life Sciences up on GBP400,000 contract win; annual loss narrows |
| 24/7/2024 | 08:52 | UK RNS | RUA Life Sciences PLC New Material Project Win |
Rua Life Sciences (RUA) Share Charts1 Year Rua Life Sciences Chart |
|
1 Month Rua Life Sciences Chart |
Intraday Rua Life Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/12/2024 | 08:00 | RUA Life Sciences - Elast-Eon Enabled MedTech | 3,810 |
| 06/4/2024 | 08:54 | purple the twat is a nasty TROLL | 24 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-13 16:08:29 | 10.62 | 350 | 37.17 | O |
| 2024-12-13 15:05:25 | 10.88 | 74,000 | 8,051.20 | O |
| 2024-12-13 14:47:18 | 10.60 | 50,000 | 5,301.10 | O |
| 2024-12-13 14:15:24 | 10.89 | 3,607 | 392.80 | O |
| 2024-12-13 14:00:25 | 10.89 | 10,000 | 1,089.00 | O |
| Top Posts |
|---|
Posted at 13/12/2024 08:20 by Rua Life Sciences Daily Update Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 11.25p.Rua Life Sciences currently has 62,060,272 shares in issue. The market capitalisation of Rua Life Sciences is ÂŁ6,826,630. Rua Life Sciences has a price to earnings ratio (PE ratio) of -4.74. This morning RUA shares opened at 11.25p |
Posted at 11/12/2024 13:26 by bones To be fair, there has been a churn of shareholders for months already. Absolutely nothing is baked into the share price about the HV and Vascular upsides so those are already discounted. Enterprise value is below book value right now and no growth potential from medical devices is in the price either. Naturally, when a share price is on the floor (it’s a moribund AIM market after all), people tend to be downcast, pessimistic and critical. Human nature, innit?The adventurous will buy at this level but RUA isn’t very visible to them which is something the company needs to rectify from a promotional viewpoint. |
Posted at 11/12/2024 11:48 by bones They’ve ditched that “broker” (Equity Development) so the only house broker is now Cavendish. They last had a 25p target which excluded any value for HV and Vascular. I hope there will be an update from them soon unless they are waiting on the completion of the ABISS net asset review.Good to see RUA left some powder dry for the next interim report, namely the expected further uplift in fair values at ABISS over and above the existing heavily written down book values as well as the catching up of the backlog of orders there. They bought ABISS almost as a favour to their main customer (which seems to be Coloplast based on the ABISS acquisition RNS) to help them out and now RUA are changing their year end to match that of Coloplast. That seems significant somehow. Certainly seems to be a solid relationship which might be beneficial if they are open to taking on more business from RUA. As pointed out, RUA also has some IP for Elasteon in the field of interest to Coloplast. The next report from RUA should provide a first indication of how cash generative ABISS might be. From an investment point of view, as Harrogate says, best to ignore HV and Vascular. I don’t believe for one moment that they are a write off but, for now, I’ll assume otherwise until there’s a specific development. |
Posted at 21/11/2024 14:42 by bones Marmie, RUA paid €80,000 for total ownership of ABISS. This was a fire sale by the French liquidator out of ABISS’s old holding company. In the last RNS, RUA estimated, based on book values, that the surplus in value over the €80k that needs to be recognised as a non-cash one off addition to assets of the RUA group is around £900k (in GBP it said). This could be subject to change once they’ve worked out what the fair values of the assets are. They probably need to put some value on the IP too. I think there’s a good chance the adjustment might be higher.Also, it sounds like ABISS is cash positive so they might be building cash having owned it for three months so far. Buying ABISS was mostly at the behest of the big customer, Coloplast, and the RUA group has now decided to realign its own year end to that of Coloplast. I don’t regard that as a coincidence. Coloplast has a vested interest in the products ABISS owns and produces for it. RUA’s other contract manufacturing business seems to be going well also. That is profitable in its own right. RUA’s R&D expenditure has been heavily curtailed to save costs too. The current weakness is probably associated with the messaging on the heart valve. There is no way the share price had been factoring in the heart valve anyway (the CM businesses are worth more than the market cap on their own) but it’s a combination of sentiment and simply being a microcap stock in an ignored AIM marketplace. I’m hoping the interims and commentary due in mid December will fill in the latest developments and be positive on these fronts. |
Posted at 21/11/2024 12:03 by cfb2 Marmie, I have pondered a similar question. I'll put myself up as a straw man so that some of the people invested here can correct me.RUA's profit was from the £900k from purchasing Abiss. From what I can discover about Abiss this was a one off but I am struggling to find out what their long term contribution to RUA might be as they are hidden within IPSAS SAS. Without Abiss, RUA are losing around £1m a year and everything BB has touched has turned to sh*t. I have looked at legal/financial liabilities pending for Abiss to justify the low liquidator price but can't find any. |
Posted at 21/11/2024 08:54 by marmiesz Hi, I'm looking into RUA and I am somewhat confused. They have £3.5M cash; made £400k pre tax profit and due to increase this. Yet the share price is sitting on a market cap of about £7M. Why?Thanks,Marmie |
Posted at 01/11/2024 07:55 by z1co Posted by NickE on lse:Good find Jimzi, and often with smaller medical device companies the P/E ratio is usually higher than that of established players. As you say we can't necessarily apply a P/E of around 64 especially as U.S. companies have a higher P/E assigned than UK stocks. Also, the 900k 'fair value' is I assume a temporary boost to the move to profitability although ABISS will accelerate the move to profitability. Regardless, markets look ahead and a value for a high growth medical device company moving to profitability with other increasingly 'oven ready' blue sky products should be a multiple of where we are now. Following on from the Aortech shareholder base, RUA's history has mainly been in the blue sky sector so value investors probably don't have it on their radar. It's almost as if the stock is punished for being both blue sky and a value play. It may be that the 50p plus valuation the stock probably deserves will only come with full or partial acquisition and on that topic some very astute posts from IntraVnus. RUA do tend to drop hints and when they spoke about doubling revenues they didn't allude to the bargain £80k acquisition but the clue was there. Maybe "the Company has changed its financial year end to better guide business planning and international business unit assimilation" is flagging up another acquisition but this time it's RUA itself. I wonder how that would pan out? They would be interested in contract manufacturing and Elast-Eon but would Coloplast have any need for Rua Vascular and Structural Heart? Unless of course they are looking to expand into long-term implants or soft tissue repair. This quarter could get interesting. |
Posted at 30/10/2024 11:05 by z1co More facts;The gross assets of Abiss at 31 December 2023 were €2,265,000. Revenue in the year to 31 December 2023 was €2,159,000 up 36% from €1,592,000 during 2023. Loss before tax was €352,000 after depreciation and amortisation charges of €537,000. In the year to 31 December 2023, Abiss had net positive cash flow of €223,000 and cash balances of €279,000 at the year end. Net Assets/Shareholders Funds at 31 December 2023 were €1,624,000. Non-current liabilities totalled €640,000 at 31 December 2023. Bill Brown, stated: "There are many similarities between Abiss and RUA Contract Manufacture, particularly with a shared customer. Abiss has been pursuing contract manufacture opportunities to further grow its business and the combined strengths of RUA and Abiss should only increase the potential. We very much look forward to working with the Abiss team and integrating into the RUA group." |
Posted at 01/10/2024 09:48 by thiopia NickEToday 09:55 Posts: 659 Price: 14.25 They have moved off NT now. Hate to tempt fate but it does look like the main seller is out now and their presence has meant the recent advances and future prospects for the Company hasn't been reflected in the share price. So it's catch up time along with the prospect of both value enhancing news (due diligence on the acquisition, further contracts for contract manufacturing) and potential transformational news - some form of deal on AurTex whether it be licensing or an outright sale of Structural Heart or the whole . The latter would quite probably take the share price into 3 figures. Nice risk reward given the seemingly positive strides towards profitability for the group as a whole and a mere 8.4m m/cap. The management seems driven in their efforts to reach profitability which has meant the stock is a bit of a hidden gem - partly because part of that effort has included cutting costs including not renewing the pr contract with Equity Development |
Posted at 05/4/2024 07:59 by parob Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignifica |
Posted at 24/11/2023 11:01 by drradcliffe What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.From their note 21/11/23: "Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update." "Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive." Does this mean the market itself wasn't expecting this trading update? I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders? If you are going to arrange a small placing, the last thing you want is a highly volatile share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
![Logo of Syntropy [NOIA Token] (NOIAUSD).](/common/images/company/COIN_NOIAUSD.png){kind=small}
